How many employees does Tarsus Pharmaceuticals, Inc. have?

Tarsus Pharmaceuticals, Inc. reported 370 employees for the fiscal year ending Dec 2025, in the annual report it filed on February 23, 2026. That is up 14.6% from a year earlier.

What is Tarsus Pharmaceuticals, Inc.'s revenue per employee?

Tarsus Pharmaceuticals, Inc. brought in $451M of revenue in fiscal Dec 2025, which is $1.22M per employee. That ranks 28 of 108 companies we track in Biotechnology, where the median is $459K.

Where do these numbers come from?

Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Company data

Tarsus Pharmaceuticals, Inc. employees and revenue per employee

TARS · Biotechnology · $3.15B market cap

Tarsus Pharmaceuticals, Inc. had 370 employees at the end of fiscal Dec 2025, up 14.6% from a year earlier. Revenue for the year was $451M, up 146.7% from a year earlier, or $1.22M per employee. Revenue and headcount both grew, and revenue grew faster.

Employees

370

+14.6% YoY

Revenue

$451M

+146.7% YoY

Revenue / employee

$1.22M

Peer median $459K

Rank in industry

28 of 108

Biotechnology

Headcount against revenue

Both lines start at 100 in the first year we hold, so you can see which one grew faster.

EmployeesRevenueIndexed to 100 in Dec 2021

Hover a year for the numbers.

TARS employees and revenue by fiscal year
Year ending	Employees	Revenue	Per employee	Staff YoY	Revenue YoY
Dec 2025	370	$451M	$1.22M	+14.6%	+146.7%
Dec 2024	323	$183M	$566K	+32.4%	+948.6%
Dec 2023	244	$17.4M	$72K	+180.5%	-32.4%
Dec 2022	87	$25.8M	$297K	+89.1%	-54.7%
Dec 2021	46	$57.0M	$1.24M	—	—

Open roles: we have not matched a verified job board for this company yet.

Employees, last six fiscal years

Revenue per employee, last six fiscal years

Tarsus Pharmaceuticals, Inc. against similar companies

The closest industry peers by revenue, from Biotechnology.

Company	Employees	Revenue	Revenue / employee	Shape
INVA Innoviva, Inc.	159	$425M	$2.67M	Hiring ahead
MIRM Mirum Pharmaceuticals, Inc.	369	$521M	$1.41M	Efficient growth
KRYS Krystal Biotech, Inc.	295	$389M	$1.32M	Efficient growth
TARS Tarsus Pharmaceuticals, Inc.	370	$451M	$1.22M	Efficient growth
ARQT Arcutis Biotherapeutics, Inc.	354	$376M	$1.06M	Efficient growth
TVTX Travere Therapeutics, Inc.	497	$491M	$987K	Efficient growth
ADMA ADMA Biologics, Inc.	647	$510M	$789K	Leaner
BBIO BridgeBio Pharma, Inc.	834	$502M	$602K	Efficient growth
TWST Twist Bioscience Corporation	979	$377M	$385K	Efficient growth

Every Healthcare company

Questions about Tarsus Pharmaceuticals, Inc.

How many employees does Tarsus Pharmaceuticals, Inc. have?: Tarsus Pharmaceuticals, Inc. reported 370 employees for the fiscal year ending Dec 2025, in the annual report it filed on February 23, 2026. That is up 14.6% from a year earlier.
What is Tarsus Pharmaceuticals, Inc.'s revenue per employee?: Tarsus Pharmaceuticals, Inc. brought in $451M of revenue in fiscal Dec 2025, which is $1.22M per employee. That ranks 28 of 108 companies we track in Biotechnology, where the median is $459K.
Where do these numbers come from?: Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Free game

Think you can pick better than the S&P 500?

Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.

Enter the challenge

More data

Compare TARS with the rest of the market

See who earns the most per employee, who is hiring, and who is cutting, across every company we track.

Leaderboard Healthcare

Source: employee counts and revenue as stated in Tarsus Pharmaceuticals, Inc.'s annual reports (Form 10-K), latest filed February 23, 2026. This is data, not a recommendation to buy or sell TARS.